Journal article
Does lactobacillus vaccine for trichomoniasis, Solco Trichovac, induce antibody reactive with Trichomonas vaginalis?
Genitourinary medicine, Vol.64(2), pp.118-123
04/1988
Handle:
https://hdl.handle.net/2376/101185
PMCID: PMC1194170
PMID: 3290091
Abstract
Solco Trichovac is a vaccine of Lactobacillus acidophilus developed for treating trichomoniasis. The efficacy of the vaccine is reportedly due to cross reacting antibody being produced in people immunised with the lactobacillus bacteria. Several techniques, including enzyme linked immunosorbent, indirect immunofluorescence, immunoblot, and radioimmunoprecipitation assays were used to assess the extent of antigenic cross reactivity between Lactobacillus acidophilus and Trichomonas vaginalis. Data show a lack of antigenic relatedness between the Solco Trichovac lactobacilli and several strains of T vaginalis. Furthermore, antiserum to L acidophilus failed to inhibit trichomonad cytadherence or host cell killing, as is suggested by the producers of the Solco Trichovac vaccine.
Metrics
11 Record Views
Details
- Title
- Does lactobacillus vaccine for trichomoniasis, Solco Trichovac, induce antibody reactive with Trichomonas vaginalis?
- Creators
- J F Alderete - Department of Microbiology, University of Texas Health Science Center, San Antonio 78284-7758
- Publication Details
- Genitourinary medicine, Vol.64(2), pp.118-123
- Academic Unit
- Molecular Biosciences, School of
- Publisher
- England
- Grant note
- AI-22380 / NIAID NIH HHS AI-18768 / NIAID NIH HHS K04-AI-00584 / NIAID NIH HHS
- Identifiers
- 99900546526301842
- Language
- English
- Resource Type
- Journal article